HTA bodies eager for EMA disclosure of clinical trial data
This article was originally published in SRA
Executive Summary
It's not only competitors and independent researchers that are keeping a watchful eye on EU plans to require the disclosure of full clinical trial data on new drugs. Health technology assessment (HTA) bodies such as Germany's IQWiG are closely monitoring developments on this front, and are particularly keen to see the clinical trial reports that the European Medicines Agency proposes to publish proactively from January next year.